Abstract Library

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#2208 High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study

Introduction: While 5HT is considered the main causative agent for carcinoid heart disease (CHD, not all pts with elevated 24h-urinary 5HIAA (u5HIAA) develop CHD.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Riechelmann R

Authors: Riechelmann R, Mesquita M, Alves C, Silva C, Soeiro M,

Keywords: carcinoid heart disease, neuroendocrine, prognostic, carcinoid syndrome,

#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors

Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Meijer W

Authors: Meijer W, Bruikman C, Beukeveld G,

Keywords: neuroendocrine tumors, chromogranin A, urinary 5HIAA, platelet serotonin,

#1751 A Case with Multiple Neuroendocrine Tumors

Introduction: Multiple endocrine neoplasia (MEN) is characterized by the occurrence of tumours involving two or more endocrine glands. MEN 1 is characterized by parathyroid adenoma, pancreaticoduodenal neuroendocrine tumors (PNTs), and pituitary adenomas.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Dermine A

Authors: Dermine A, Deslé M, Filleul B, Seront E, Lejeune S,

Keywords: neuroendocrine tumor, MEN,

#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors

Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Khan M

Authors: Khan M, Tsigani T, Rashid M, Luong T, Caplin M,

Keywords: neuroendocrine tumor, circulating tumor cells, carcinoid, EpCAM,